Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
07 January 2018 Photo Charl Devenish
Researcher tackling drug-resistant TB through molecular methods
Dr Anneke van der Spoel van Dijk is invested in contributing to the global effort of stopping TB by 2035.

The work of Dr Anneke van der Spoel van Dijk investigates the spread of TB in the Free State population using techniques such as next generation sequencing, spoligotyping and MIRU-VNTR typing. Dr Van der Spoel van Dijk, a senior medical scientist in the Department of Medical Microbiology at the University of the Free State (UFS) also looks at drug resistance in her research. This work informs decisions about how best to treat patients with multidrug-resistant TB (MDR-TB). 

She employs rapid molecular techniques to track one of Africa’s most serious diseases, tuberculosis (TB). 

Drug resistance
Scientists assist the National Health Laboratory Service and Department of Health in trying to refine the diagnostic tools to identify these cases earlier. Dr Van der Spoel van Dijk explains: “Until recently, it took up to two years to fine-tune treatment decisions for patients with MDR-TB. Patients get a cocktail of anti-TB drugs, but it takes time to find the right combination. Re-infection and relapse (patients stopping treatment for several reasons) add to the diagnostic and treatment management challenges.

Enormous impact
“Now doctors can reduce the time needed for diagnostic certainty to about seven days, while new drugs allow reduction of treatment from more than 18 to nine months. This can have an enormous impact on the life of many patients.”

Dr Van der Spoel van Dijk’s work forms part of research in the faculty looking at resistance development in TB strains. She is currently also doing her doctoral thesis on the differences and incidence of MDR-TB among adolescents versus adults. Dr Van der Spoel van Dijk says: “It is a complicated picture, but we hope to unravel it to support better diagnostic tools and patient care.”

As part of the National Health Laboratory Service, her department is playing an important role in TB diagnostics and the training of scientists and future pathologists. “Our work is contributing to the global vision to stop TB by 2035,” Dr Van der Spoel van Dijk says.

News Archive

UFS takes a leading role in nuclear medicine and technology
2011-12-06

 
Photo: Dr Glen Taylor

The University of the Free State (UFS) continues to play an active role in the field of Nuclear Medicine and the use of nuclear technology in the biosciences. Dr Glen Taylor, Director of Research Commercialisation and Business Development at the UFS, was recently elected chairperson of the board for the Nuclear Technologies in Medicine and the Biosciences Initiative (NTeMBI).

The UFS is currently one of three centres of excellence in the country identified by the Nuclear Energy Corporation South African (Necsa) to roll out the capacity development programme and increase technology coming from nuclear medicine and technology.
NTeMBI is a national technology platform that is managed by Necsa and supported by the Department of Science and Technology (DST). It functions as a high-level Research, Development and Innovation (RD&I) initiative that will implement new strategic initiatives relating to research and development on nuclear technologies in medicine and the biosciences on a local, regional and international level. 
 
One of the roles Dr Taylor will perform as Chairperson of the board of NTeMBI, is to enhance the exposure of nuclear technology in medicine and the biosciences. Dr Taylor says the aim is to increase the skills base in South Africa. “I realise it is one of the scare skills in the country.” 
 
The UFS already received a significant amount of funding from the grant of R4 million per annum made available from the Department of Science and Technology (DST) to implement NTeMBI projects.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept